Two-Year-Old Children Included in Gene Therapy Indication as Sickle Cell Care Faces One-Time Treatment Earlier
The FDA’s expanded pediatric approval of Vertex’s gene therapy pushes treatment options earlier in the disease course; the real challenge will lie in whether evidence in young children, transplant-like procedures, and years of follow-up can bear this promise.